Trojan horse” approach may enable ‘antigen-independent’ therapy with potential to treat cancers not traditionally amenable to immunotherapy.

Amlitelimab, an OX40 ligand–targeting therapy that modulates T-cell-mediated inflammation without causing cell depletion, ...

Janux Therapeutics struck a global licensing deal for its tumor-activated platforms, sending shares higher and expanding its reach in solid tumors.

Sanofi's amlitelimab confirms its potential in atopic dermatitis: Paris Saturday, January 24, 2026, 10:00 Hrs [IST] Following the positive COAST 1 (clinical study identifier: NCT0 ...

Key market opportunities in CD137-targeted therapies include the upcoming commercial launch by 2030, robust clinical trial activity with over 90 therapies, and promising combination therapies.

Corvus currently expects to use the net proceeds from this offering for working capital and general corporate purposes, which may include capital expenditures and research and development, including ...

Amlitelimab is an investigational anti-OX40 ligand monoclonal antibody designed to normalize the overactive immune response in patients with atopic dermatitis.

Detailed price information for Janux Therapeutics Inc (JANX-Q) from The Globe and Mail including charting and trades.

Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the closing of an upsized underwritten ...

In response to today's news over whether long?standing vaccine recommendations remain necessary, I want to publicly stress strong support for science?based immunization schedules and the incredible ...

At the World Economic Forum, CEO Stéphane Bancel expressed concern about the US vaccine market but remained committed to ...